

BRETT GUTHRIE, KENTUCKY  
CHAIRMAN

FRANK PALLONE, JR., NEW JERSEY  
RANKING MEMBER

ONE HUNDRED NINETEENTH CONGRESS  
**Congress of the United States**  
**House of Representatives**  
**COMMITTEE ON ENERGY AND COMMERCE**

2125 RAYBURN HOUSE OFFICE BUILDING  
WASHINGTON, DC 20515-6115  
Majority (202) 225-3641  
Minority (202) 225-2927

March 21, 2025

Mr. Shawn Gremminger, MPH  
President and CEO  
National Alliance of Healthcare Purchaser Coalitions  
1015 18th Street NW, Suite 705  
Washington, DC 20036

Dear Mr. Gremminger:

Thank you for appearing before the Subcommittee on Health on Wednesday, February 26, 2025, to testify at the hearing entitled "An Examination of How Reining in PBMs Will Drive Competition and Lower Costs for Patients."

Pursuant to the Rules of the Committee on Energy and Commerce, the hearing record remains open for ten business days to permit Members to submit additional questions for the record, which are attached. The format of your responses to these questions should be as follows: (1) the name of the Member whose question you are addressing, (2) the complete text of the question you are addressing in bold, and (3) your answer to that question in plain text.

To facilitate the printing of the hearing record, please respond to these questions with a transmittal letter by the close of business on Friday, April 4, 2025. Your responses should be mailed to Emma Schultheis, Legislative Clerk, Committee on Energy and Commerce, 2125 Rayburn House Office Building, Washington, DC 20515 and e-mailed in Word format to [Emma.Schultheis@mail.house.gov](mailto:Emma.Schultheis@mail.house.gov).

Thank you again for your time and effort preparing and delivering testimony before the Subcommittee.

Sincerely,



Earl L. "Buddy" Carter  
Chairman  
Subcommittee on Health

cc: Diana DeGette, Ranking Member, Subcommittee on Health

Attachment

## **Attachment — Additional Questions for the Record**

### **The Honorable Troy Balderson**

1. Over the past few years, we have seen pharmacy benefit managers (PBMs) and their affiliated group purchasing organizations (GPOs) increase the use of service fees, for instance requiring manufacturers to pay for access to necessary information or data. The rapid rise in these so-called service fees is just an example of the onerous challenges PBMs and GPOs are inflicting on manufacturers. These fees are designed for profits, they are not designed to reduce costs for patients. How should we ensure that these fees are truly bona fide?
  - a. What do you predict PBMs and their affiliated GPOs will do next in their efforts to maximize profits at the expense of patients and taxpayers?